IL-6 has been shown to be involved in many physiologic activities, disease initiation and progression. Serum IL-6 levels were also upregulated during recent outbreak of new coronavirus infection (SARS-CoV-2). IL-6 levels are significantly lower in mild compared with severe and critically ill groups of patients with SARS-CoV-2. IL-6 levels are associated with severity of COVID-19 infection. Moreover, IL-6 could be a predictive marker of survival in COVID-19 patients outperforming CRP, D-dimer, and ferritin, independently of demographics and comorbidities.
Baseline levels of human IL-6 in the blood is known to be in single pg/ml digits and can increase up to thousands pg/ml upon severe sepsis, therefore assays characterized by high sensitivity and wide diagnostic window are needed for reliable determination of IL-6 in the bloodstream.
Interleukin-6 (IL-6) participates in inflammation, immune response and acts in the coordination of developmental, neuronal, and metabolic processes. IL-6 acts as transmitter of alarm signal to whole organism indicating occurrence of an emergency such as infection or tissue damage.
We have now developed 7 new MAb pairs to IL-6 that are suitable for high sensitivity IL-6 assay development (Cat# 4IL6) and a recombinant antigen suitable as a calibrator (Cat# 8IL6). The new antibodies have low cross-reactivity to other cognate interleukin human proteins, which secure a very high assay specificity as well.
Figure 1. Linearity of dilution using new HyTest IL-6 mAbs.